Vivos Therapeutics (VVOS): 2025 Results and Path to Cash Flow Breakeven by End-2026

On this episode, Vivos Therapeutics (NASDAQ: VVOS) CEO Kirk Huntsman joins WTR’s Tim Gerdeman and Robert Sassoon on Healthcare Happenings to discuss the company’s 2025 results and the momentum behind its shift from a dentist‑led model to a medically integrated strategy centered on sleep centers and physician referrals, anchored by the Sleep Center of Nevada acquisition. Huntsman highlights strong validation of the new model despite temporary 4Q25 staffing and payer delays, which are now largely resolved. The conversation covers improving patient treatment conversion, infrastructure expansion, rising cardiology and hospital referrals tied to OSA risk, and Vivos’ path toward cash‑flow breakeven by end‑2026.